Kyntra Bio (KYNB) Competitors

$7.10 -0.10 (-1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$7.12 +0.03 (+0.35%)

As of 04:04 PM Eastern

KYNB vs. PEPG, CGTX, FRMM, ALTS, and TTRX

Should you be buying Kyntra Bio stock or one of its competitors? The main competitors of Kyntra Bio include PepGen (PEPG), Cognition Therapeutics (CGTX), Forum Markets (FRMM), ALT5 Sigma (ALTS), and Turn Therapeutics (TTRX). These companies are all part of the "pharmaceutical products" industry.

How does Kyntra Bio compare to PepGen?

Kyntra Bio (NASDAQ:KYNB) and PepGen (NASDAQ:PEPG) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

: Kyntra Bio has a net margin of 2,848.19% compared to PepGen's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat PepGen's return on equity.
Company Net Margins Return on Equity Return on Assets
Kyntra Bio 2,848.19% N/A -34.39%
PepGen N/A -75.73% -60.42%
: PepGen has a consensus target price of $11.80, suggesting a potential upside of 511.40%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Kyntra Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
PepGen
1 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
: In the previous week, Kyntra Bio and Kyntra Bio both had 2 articles in the media. PepGen's average media sentiment score of 0.62 beat Kyntra Bio's score of 0.00 indicating that PepGen is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyntra Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PepGen
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Kyntra Bio has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kyntra Bio $6.44M 4.47 $183.45M $45.47 0.16
PepGen N/A N/A -$89.65M -$2.41 N/A
: Kyntra Bio has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, PepGen has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.
: 72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Comparatively, 4.6% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,848.19%	N/A	-34.39%
PepGen	N/A	-75.73%	-60.42%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.47	$183.45M	$45.47	0.16
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A

Summary

Kyntra Bio beats PepGen on 9 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

: Cognition Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
: Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 168.82%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than Kyntra Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Kyntra Bio
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
: 43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by company insiders. Comparatively, 2.0% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: In the previous week, Kyntra Bio had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 2 mentions for Kyntra Bio and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cognition Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kyntra Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Kyntra Bio has a net margin of 2,848.19% compared to Cognition Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Cognition Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Cognition Therapeutics N/A -104.27% -69.64%
Kyntra Bio 2,848.19% N/A -34.39%
: Kyntra Bio has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cognition Therapeutics N/A N/A -$23.49M -$0.33 N/A
Kyntra Bio $6.44M 4.47 $183.45M $45.47 0.16

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-104.27%	-69.64%
Kyntra Bio	2,848.19%	N/A	-34.39%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.33	N/A
Kyntra Bio	$6.44M	4.47	$183.45M	$45.47	0.16

Summary

Kyntra Bio beats Cognition Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Forum Markets?

Kyntra Bio (NASDAQ:KYNB) and Forum Markets (NASDAQ:FRMM) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

: In the previous week, Kyntra Bio and Kyntra Bio both had 2 articles in the media. Kyntra Bio's average media sentiment score of 0.00 equaled Forum Markets'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyntra Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Forum Markets
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Kyntra Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Forum Markets has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
: Kyntra Bio has higher earnings, but lower revenue than Forum Markets. Forum Markets is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kyntra Bio $6.44M 4.47 $183.45M $45.47 0.16
Forum Markets $6.55M 15.23 -$450.52M -$39.19 N/A
: 72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 2.0% of Kyntra Bio shares are owned by company insiders. Comparatively, 15.1% of Forum Markets shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Forum Markets has a consensus price target of $5.00, suggesting a potential upside of 1.83%. Given Forum Markets' higher probable upside, analysts clearly believe Forum Markets is more favorable than Kyntra Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
Forum Markets
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Kyntra Bio has a net margin of 2,848.19% compared to Forum Markets' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Forum Markets' return on equity.
Company Net Margins Return on Equity Return on Assets
Kyntra Bio 2,848.19% N/A -34.39%
Forum Markets N/A -254.74% -132.82%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.47	$183.45M	$45.47	0.16
Forum Markets	$6.55M	15.23	-$450.52M	-$39.19	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,848.19%	N/A	-34.39%
Forum Markets	N/A	-254.74%	-132.82%

Summary

Kyntra Bio beats Forum Markets on 9 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to ALT5 Sigma?

Kyntra Bio (NASDAQ:KYNB) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

: In the previous week, ALT5 Sigma had 3 more articles in the media than Kyntra Bio. MarketBeat recorded 5 mentions for ALT5 Sigma and 2 mentions for Kyntra Bio. ALT5 Sigma's average media sentiment score of 0.11 beat Kyntra Bio's score of 0.00 indicating that ALT5 Sigma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyntra Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ALT5 Sigma
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Kyntra Bio has a net margin of 2,848.19% compared to ALT5 Sigma's net margin of -1,386.90%. Kyntra Bio's return on equity of 0.00% beat ALT5 Sigma's return on equity.
Company Net Margins Return on Equity Return on Assets
Kyntra Bio 2,848.19% N/A -34.39%
ALT5 Sigma -1,386.90% -50.52% -45.05%
: Kyntra Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.
: Kyntra Bio has higher earnings, but lower revenue than ALT5 Sigma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kyntra Bio $6.44M 4.47 $183.45M $45.47 0.16
ALT5 Sigma $24.84M 4.20 -$344.51M N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
ALT5 Sigma
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,848.19%	N/A	-34.39%
ALT5 Sigma	-1,386.90%	-50.52%	-45.05%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.47	$183.45M	$45.47	0.16
ALT5 Sigma	$24.84M	4.20	-$344.51M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Kyntra Bio beats ALT5 Sigma on 9 of the 13 factors compared between the two stocks.

How does Kyntra Bio compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Kyntra Bio (NASDAQ:KYNB) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

: Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 116.22%. Given Turn Therapeutics' higher possible upside, equities research analysts plainly believe Turn Therapeutics is more favorable than Kyntra Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Kyntra Bio
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
: Kyntra Bio has a net margin of 2,848.19% compared to Turn Therapeutics' net margin of 0.00%.
Company Net Margins Return on Equity Return on Assets
Turn Therapeutics N/A N/A N/A
Kyntra Bio 2,848.19% N/A -34.39%
: Kyntra Bio has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Turn Therapeutics N/A N/A -$3.19M -$0.16 N/A
Kyntra Bio $6.44M 4.47 $183.45M $45.47 0.16
: 72.7% of Kyntra Bio shares are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Kyntra Bio had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 2 mentions for Kyntra Bio and 0 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.
Company Overall Sentiment
Turn Therapeutics Neutral
Kyntra Bio Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Kyntra Bio	2,848.19%	N/A	-34.39%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.16	N/A
Kyntra Bio	$6.44M	4.47	$183.45M	$45.47	0.16

Company	Overall Sentiment
Turn Therapeutics	Neutral
Kyntra Bio	Neutral

Summary

Kyntra Bio beats Turn Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Kyntra Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYNB vs. The Competition

Export

Metric	Kyntra Bio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$28.76M	$892.88M	$4.21B	$11.87B
Dividend Yield	N/A	4.84%	5.61%	5.21%
P/E Ratio	0.16	1.72	23.40	28.47
Price / Sales	4.47	120.50	186.85	60.94
Price / Cash	N/A	20.07	52.82	36.52
Price / Book	-1.69	7.60	38.31	6.67
Net Income	$183.45M	-$4.80M	$114.66M	$332.53M
7 Day Performance	0.71%	-0.02%	1.23%	2.01%
1 Month Performance	1.28%	5.52%	5.54%	9.20%
1 Year Performance	N/A	30.99%	18.68%	39.59%

Kyntra Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYNB Kyntra Bio	0.9308 of 5 stars	$7.10 -1.4%	N/A	N/A	$28.76M	$6.44M	0.16	570	News Coverage
PEPG PepGen	2.7387 of 5 stars	$1.75 +6.7%	$11.80 +574.3%	N/A	$113.44M	N/A	N/A	30
CGTX Cognition Therapeutics	2.9237 of 5 stars	$1.28 +1.6%	$3.33 +160.4%	N/A	$112.59M	N/A	N/A	20	Upcoming Earnings
FRMM Forum Markets	0.3138 of 5 stars	$5.85 +6.9%	$5.00 -14.5%	N/A	$111.11M	$6.55M	N/A	7
ALTS ALT5 Sigma	N/A	$0.88 +2.6%	N/A	N/A	$110.80M	$24.84M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYNB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyntra Bio (KYNB) Competitors

KYNB vs. PEPG, CGTX, FRMM, ALTS, and TTRX

How does Kyntra Bio compare to PepGen?

Summary

How does Kyntra Bio compare to Cognition Therapeutics?

Summary

How does Kyntra Bio compare to Forum Markets?

Summary

How does Kyntra Bio compare to ALT5 Sigma?

Summary

How does Kyntra Bio compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyntra Bio (KYNB) Competitors

KYNB vs. PEPG, CGTX, FRMM, ALTS, and TTRX

How does Kyntra Bio compare to PepGen?

Summary

How does Kyntra Bio compare to Cognition Therapeutics?

Summary

How does Kyntra Bio compare to Forum Markets?

Summary

How does Kyntra Bio compare to ALT5 Sigma?

Summary

How does Kyntra Bio compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools